These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 38711620)

  • 21. Tumor microenvironment signaling and therapeutics in cancer progression.
    Goenka A; Khan F; Verma B; Sinha P; Dmello CC; Jogalekar MP; Gangadaran P; Ahn BC
    Cancer Commun (Lond); 2023 May; 43(5):525-561. PubMed ID: 37005490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal cells in the tumor microenvironment: accomplices of tumor progression?
    Zhao Y; Shen M; Wu L; Yang H; Yao Y; Yang Q; Du J; Liu L; Li Y; Bai Y
    Cell Death Dis; 2023 Sep; 14(9):587. PubMed ID: 37666813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.
    Mehraj U; Ganai RA; Macha MA; Hamid A; Zargar MA; Bhat AA; Nasser MW; Haris M; Batra SK; Alshehri B; Al-Baradie RS; Mir MA; Wani NA
    Cell Oncol (Dordr); 2021 Dec; 44(6):1209-1229. PubMed ID: 34528143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering approaches for innate immune-mediated tumor microenvironment remodeling.
    Kane GI; Lusi CF; Brassil ML; Atukorale PU
    Immunooncol Technol; 2024 Mar; 21():100406. PubMed ID: 38213392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recapitulating the Cancer-Immunity Cycle on a Chip.
    Lee Y; Min J; Kim S; Park W; Ko J; Jeon NL
    Adv Healthc Mater; 2024 Sep; ():e2401927. PubMed ID: 39221688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic strategies to remodel immunologically cold tumors.
    Wang M; Wang S; Desai J; Trapani JA; Neeson PJ
    Clin Transl Immunology; 2020; 9(12):e1226. PubMed ID: 35136604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application and prospect of microfluidic devices for rapid assay of cell activities in the tumor microenvironment.
    Zhu L; Cui X; Jiang L; Fang F; Liu B
    Biomicrofluidics; 2024 May; 18(3):031506. PubMed ID: 38899164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.
    Li YR; Fang Y; Lyu Z; Zhu Y; Yang L
    J Transl Med; 2023 Oct; 21(1):686. PubMed ID: 37784157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?
    Wang J; Loeuillard E; Gores GJ; Ilyas SI
    Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor microenvironment as a complex milieu driving cancer progression: a mini review.
    Li Z; Li J; Bai X; Huang X; Wang Q
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39342061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Tumor Immunosuppressive Microenvironment for the Prevention of Hepatic Cancer: Applications of Traditional Chinese Medicines in Targeted Delivery.
    Zhang LY; Zhang JG; Yang X; Cai MH; Zhang CW; Hu ZM
    Curr Top Med Chem; 2020; 20(30):2789-2800. PubMed ID: 33076809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Tumour-Associated Fibroblasts in Cancers.
    Shah K; Mallik SB; Gupta P; Iyer A
    Front Oncol; 2022; 12():908156. PubMed ID: 35814453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics.
    Akinsipe T; Mohamedelhassan R; Akinpelu A; Pondugula SR; Mistriotis P; Avila LA; Suryawanshi A
    Front Immunol; 2024; 15():1302587. PubMed ID: 38533507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microfluidic technologies for immunotherapy studies on solid tumours.
    Paterson K; Zanivan S; Glasspool R; Coffelt SB; Zagnoni M
    Lab Chip; 2021 Jun; 21(12):2306-2329. PubMed ID: 34085677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting tumor microenvironment and metastasis in children with solid tumors.
    Wessel KM; Kaplan RN
    Curr Opin Pediatr; 2022 Feb; 34(1):53-60. PubMed ID: 34812775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the tumor microenvironment: Potential strategy for cancer therapeutics.
    Babar Q; Saeed A; Tabish TA; Sarwar M; Thorat ND
    Biochim Biophys Acta Mol Basis Dis; 2023 Aug; 1869(6):166746. PubMed ID: 37160171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer.
    Economopoulou P; Kotsantis I; Psyrri A
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33203092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications.
    Fang J; Lu Y; Zheng J; Jiang X; Shen H; Shang X; Lu Y; Fu P
    Cell Death Dis; 2023 Sep; 14(9):586. PubMed ID: 37666809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology.
    Xie H; Appelt JW; Jenkins RW
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomimetic Model of Tumor Microenvironment on Microfluidic Platform.
    Chung M; Ahn J; Son K; Kim S; Jeon NL
    Adv Healthc Mater; 2017 Aug; 6(15):. PubMed ID: 28544639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.